Back to search results

Study of Calaspargase Pegol-mknl, Decitabine, and Venetoclax for T-ALL/T-LLy

This study is looking into whether a combination of three medicines—calaspargase pegol-mknl, decitabine, and venetoclax—can help children, teenagers, and young adults with T-cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LLy) that has come back or not responded to previous treatments. Calaspargase pegol-mknl and decitabine are given through a vein, while venetoclax is taken by mouth. The main goal is to see how safe this combination is and if it can lead to a complete response (meaning the cancer is no longer detectable). The study plans to enroll 22 participants aged 1 month to 21 years. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 22 participants. It aims to evaluate the efficacy and safety of a drug combination.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety and adverse events will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06561074

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

Recruiting
PHASE2Ages 1–21InterventionalTreatment
M.D. Anderson Cancer Center
~22 participants
Updated 2026-07-23 on ClinicalTrials.gov
What's tested:DecitabineVenetoclaxCalaspargase pegol-mknl

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and adverse events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

T-cell Acute Lymphoblastic Leukemia
T-Cell Lymphoblastic Lymphoma

Explore related trials

Pre T-ALLT Lymphoblastic Lymphoma

NCT06561074

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • MD Anderson Cancer Center

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • David McCall, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

David McCall, MD
[email protected]
(713) 792-6604
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Safety and adverse events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0